Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Authors Todd M Cooper

Published 15 January 2008 Volume 2007:3(6) Pages 1135—1141

Todd M Cooper
Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Abstract: T-cell malignancies have distinct biochemical, immunologic, and clinical features which set them apart from non-T-cell malignancies. In the past, T-cell leukemia portended a worse prognosis than leukemia of B-cell origin. Cure rates have improved with intensification of therapy and advanced understanding of the molecular genetics of T-cell malignancies. Further advances in the treatment of T-cell leukemia will require the development of novel agents that can target specific malignancies without a significant increase in toxicity. Nelarabine (2-amino-
9β-D-arabinosyl-6-methoxy-9H-guanine), a synthesized guanosine nucleoside prodrug of ara-G (9-β-D-arabinofuranosylguanine), recently received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory T-ALL and T-LBL in adults and children. Nelarabine is water soluble and rapidly converted to ara-G, which is specifically cytotoxic to T-lymphocytes and T-lymphoblastoid cells. Clinical and pharmacokinetic investigations have established that nelarabine is active as a single agent which has led to exploration of an expanded role in the treatment of T-cell hematologic malignances.
Keywords: T-cell acute lymphoblastic leukemia, nelarabine, 9-β-D-arabinofuranosylguanine

Download Article [PDF] 

Readers of this article also read:

Prediction and prevention of the first psychotic episode: new directions and opportunities

Piras S, Casu G, Casu MA, Orrù A, Ruiu S, Pilleri A, Manca G, Marchese G

Therapeutics and Clinical Risk Management 2014, 10:241-253

Published Date: 28 March 2014

Erratum

Rapidis A, Sarlis N, Lefebvre J-L, et al

Therapeutics and Clinical Risk Management 2008, 4:1381-1381

Published Date: 5 December 2008

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Zinelabidine Abouelfadel, E David Crawford

Therapeutics and Clinical Risk Management 2008, 4:513-526

Published Date: 11 April 2008

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists

Hans P Schlecht, Sarah Schellhorn, Bruce J Dezube, Jeffrey M Jacobson

Therapeutics and Clinical Risk Management 2008, 4:473-485

Published Date: 11 April 2008

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

Evaluation of patient care interventions and recommendations by a transitional care pharmacist

K Bruce Bayley, Lucy A Savitz, Teresa Maddalone, Stephen E Stoner, Jacquelyn S Hunt, Robert Wells

Therapeutics and Clinical Risk Management 2007, 3:695-703

Published Date: 15 September 2007

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007

An assessment of the cost-utility of therapy for psoriasis

Stefan C Weiss, Wingfield Rehmus, Alexa B Kimball

Therapeutics and Clinical Risk Management 2006, 2:325-328

Published Date: 15 September 2006